Barclays’s Pharvaris PHVS Stock Holding History

Barclays’s Portfolio PHVS Stock Details PHVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$173K	Buy	+5,000	New	+$151K	﹤0.01%	3794

Other funds holding PHVS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EFM

EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Barclays's PHVS Position: Q2 2026 in Review

Barclays increased its Pharvaris (PHVS) stake by 374% in Q2 2026, buying an estimated $494K and bringing the position to 20,702 shares worth $716K. The position accounts for ﹤0.01% of the portfolio, ranked #2994.

Barclays first reported a position in PHVS in Q3 2024 and has held it in 7 quarters since. 125 funds tracked by Wall St. Rank hold PHVS as of Q2 2026.

Barclays held 20,702 shares of Pharvaris worth $716K as of Q2 2026.
Barclays bought 16,334 Pharvaris shares in Q2 2026, an estimated $494K.
Pharvaris made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2994 holding.
Barclays first reported a position in Pharvaris in Q3 2024 and has held it in 7 quarters since.
125 funds tracked by Wall St. Rank held Pharvaris as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.